http://theweek.com/articles/716832/free-martin-shkreli
This paper is provocative.
The point is orphan drugs.
And the journalist is right, without prices which allow R&D and high quality production for those rare diseases there will not be any drug available and the situation of patients will be without hope.
It is already the case for some orphan diseases or non orphan diseases in countries where prices are set by government. This finally end in drug shortages.
vendredi 6 avril 2018
Inscription à :
Publier les commentaires (Atom)
Aucun commentaire:
Enregistrer un commentaire